Rise Advisors’s Akero Therapeutics AKRO Stock Holding History

Rise Advisors’s Portfolio AKRO Stock Details AKRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-22	Closed	-$891	–	1542
2025 Q1	$891	Buy	+22	New	+$933	﹤0.01%	1296

Other funds holding AKRO

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Rise Advisors's AKRO Position: Q2 2025 in Review

Rise Advisors sold out of Akero Therapeutics (AKRO) in Q2 2025, closing a stake of 22 shares — an estimated $891 sold.

Rise Advisors first reported a position in AKRO in Q1 2025 and held it in 1 quarter. The position peaked at $891 in Q1 2025. 257 funds tracked by Wall St. Rank hold AKRO as of Q2 2025.

Rise Advisors reported no remaining Akero Therapeutics position as of Q2 2025 after selling out during the quarter.
Rise Advisors sold 22 Akero Therapeutics shares in Q2 2025, an estimated $891.
Rise Advisors first reported a position in Akero Therapeutics in Q1 2025 and held it in 1 quarter.
Rise Advisors's Akero Therapeutics position peaked at $891 in Q1 2025.
257 funds tracked by Wall St. Rank held Akero Therapeutics as of Q2 2025.

Based on Rise Advisors's 13F filing for Q2 2025, filed 8 Jul 2025.